Business Model Breakdown
How Vicarious Surgical Inc Makes Money
RBOT
Market Cap
$4M
The Short Version
Vicarious Surgical Inc. is developing a next-generation surgical robotics system designed to give surgeons the ability to operate internally through a single incision, mimicking human motion through miniature humanoid-like arms. The company's business model intends to generate revenue primarily through the sale of its proprietary robotic surgical systems, as well as recurring revenue from consumables and service contracts once the product achieves regulatory approval and commercialization. Currently, the company is pre-revenue, focused solely on research, development, and clinical trials for its innovative technology.
Where the Revenue Comes From
System Sales (0% of revenue, projected future)
Consumables & Service (0% of revenue, projected future)
Who buys: Hospitals, surgical centers, and healthcare providers (projected future customers).
Why It Works (Competitive Advantages)
- ✔Novel form factor and proprietary technology for minimally invasive abdominal surgery, designed to be smaller and more versatile than traditional systems.
- ✔Potential for improved surgical access in constrained spaces.
Economic Moat: None (Intangible Assets/IP (Patents for novel robotic design))
What Our Analysis Says
DVR Score as of June 7, 2026
The score has declined slightly from 2.2/10 (22/100) to 1.8/10 (18/100) due to the increased immediacy of the previously identified financial crisis. As of today, June 7, 2026, the company's projected cash runway through Q2 2026 (ending June 30) is almost exhausted, without any new positive funding or operational updates confirmed in the provided real-time intelligence. This heightens the financial risk and uncertainty regarding its ability to continue operations, execute its strategic pivot, and pursue a Nasdaq relisting. The core technology retains potential, but the immediate and severe liquidity issues, combined with its OTC status and planned dilutive reverse split, severely diminish its path to 10x growth within the target timeframe. Without a confirmed, substantial capital infusion, the company faces significant going-concern risks.